Mylan NV’s planned merger with Pfizer Inc’s off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment.
Mylan deal puts future of its beleaguered EpiPen in spotlight
